In the pirfenidone group , as compared with the placebo group , there was a relative reduction of @ % in the proportion of patients who had an absolute decline of @ percentage points or more in the percentage of the predicted FVC or who died ; there was also a relative increase of @ % in the proportion of patients with no decline in FVC ( P < @ ) .